In HER2-positive early breast cancer, Kadcyla shows sustained improvement in both invasive disease-free survival and overall survival versus Herceptin.

HER2-positive breast cancer may be a misnomer, according to a growing body of evidence that one of the most widely ... By the late ’90s, a drug called Herceptin that targeted the HER2 receptor, sped ...

the body often makes too much of the HER2neu protein, and cells can grow out of control. HER2-positive breast cancers can be very aggressive. For several years, the drug Herceptin has been used to ...

These proteins are designed to recognise and bind to other unique proteins in the body. Herceptin SC binds selectively to a protein called human epidermal growth factor receptor 2 (HER2).

Many experts are frustrated and troubled by the state of HER2 testing, especially as new opportunities for tests are on the horizon. And as trials testing Herceptin at earlier stages and in ...

Novel HER2 therapies show strong intracranial efficacy, enabling systemic treatment over local therapy for small, ...

Experts discuss the patient case of Janet, a 58-year-old with her 2 positive metastatic breast cancer, and after 14 months on ...

In this randomized controlled trial, adjuvant trastuzumab emtansine (T-DM1) reduced invasive disease events in patients with ...

Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...

The mode of action of Herceptin activates the body's immune system and suppresses HER2 signalling to target and destroy the tumour. The drug was first approved in 1998 and has been used to treat ...